|
HP1BP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.96429547574917E-14 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
7.336800E-01 |
| Stage1-vs-Stage3 |
1.111030E-01 |
| Stage1-vs-Stage4 |
4.855800E-03 |
| Stage2-vs-Stage3 |
4.436400E-01 |
| Stage2-vs-Stage4 |
9.904100E-02 |
| Stage3-vs-Stage4 |
2.953800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.81670000551659E-08 |
| Normal-vs-Asian |
1.22124532708767E-14 |
| Caucasian-vs-AfricanAmerican |
2.167000E-01 |
| Caucasian-vs-Asian |
5.330800E-01 |
| AfricanAmerican-vs-Asian |
4.654600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.091200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
2.08109999999539E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.804400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.458000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.728800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.199410E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.039600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.296000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.849600E-04 |
| Classical-VS-Follicular |
5.288600E-01 |
| Classical-VS-Other |
2.956400E-01 |
| Classical-VS-Normal |
8.77076189453874E-15 |
| Tall-VS-Follicular |
2.657600E-02 |
| Tall-VS-Other |
6.432400E-01 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
5.641200E-01 |
| Follicular-VS-Normal |
1.62925228863742E-12 |
| Other-VS-Normal |
2.06779999999407E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.727600E-01 |
|
|
